Nuvectis Pharma Inc expected to post a loss of 34 cents a share - Earnings Preview

Nuvectis Pharma

01/11/2023 12:04

* Nuvectis Pharma Inc  NVCT.OQ   NVCT.O  is expected to show
no
change in quarterly revenue when it reports  results 
    * 
    * ​Refinitiv's mean analyst estimate for Nuvectis Pharma Inc
is
for a loss of 34 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Nuvectis
Pharma
Inc is $21​, above​ its last closing price of $8.95. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -0.29       -0.29      -0.38     Missed  -30.3
 Mar. 31 2023  -0.44       -0.44      -0.27     Beat    38.8
 Dec. 31 2022              -0.38                        ​
 Sep. 30 2022  -0.27       -0.27      -0.42     Missed  -55.6
 ​​Jun.        -0.22       -0.23      -0.28     Missed  -20
 30 2022                                                
 Mar. 31 2022  -0.23       -0.23      -0.32     Missed  -39.1​
 Dec. 31 2021  -0.85       -0.85      -0.48     Beat    43.5
 This summary was machine generated November 1 at 12:04 GMT.  All
figures in US dollars  unless otherwise stated